Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v3.8.0.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 7,522 $ 14,006
Restricted cash 361 0
Receivables 65 3,587
Prepaid expenses and other current assets 362 237
Total current assets 8,310 17,830
Property and equipment, net 595 837
Total Assets 8,905 18,667
Current liabilities:    
Accounts payable 821 3,015
Accrued clinical trials expenses 289 1,387
Other accrued liabilities 354 455
Current portion of long-term debt 3,000 0
Total current liabilities 4,464 4,857
Long-term debt, net of debt discount of $497,000 3,584 0
Warrant liability 0 619
Total Liabilities 8,048 5,476
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2017 and 2016. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 125,000,000 shares authorized, 21,203,744 and 21,198,879 shares issued and outstanding at December 31, 2017 and 2016, respectively. 297,855 297,855
Additional paid-in capital 26,273 24,300
Accumulated deficit (323,271) (308,964)
Total stockholders’ equity 857 13,191
Total Liabilities and Stockholders’ Equity $ 8,905 $ 18,667